98 innovative vaccines in development by Vaccines Europe member companies

Vaccines Europe published the third edition of its annual pipeline review today, 2^nd December. The report showcases the innovative vaccines in clinical development by the Vaccines Europe member companies and highlights the transformative power of vaccines and monoclonal antibodies in addressing evolving health challenges such as antimicrobial resistance (AMR), climate change and the ageing population. 

There are 98 vaccines in development by Vaccines Europe member companies across 12 different technology platforms. 42% of them address diseases for which no vaccine has been registered, for example, HIV, Salmonella infection and Lyme disease; while 58% aim to further develop existing vaccines or find a new approach to address a disease.  

The impact of vaccination on public health extends well beyond the established childhood immunisation programmes. The pipeline review shows over 80% of the vaccines in development by Vaccines Europe members are for adults. Immunisation for all people, including adults and older adults, pregnant individuals, and those with chronic health conditions such as cardiovascular diseases, is key to safeguarding public health, as demonstrated by the safe and effective vaccines developed to tackle the COVID-19 pandemic, and the success of HPV vaccination programmes. Recent evidence demonstrated that adult immunisation returns 19 times its initial investment when the full spectrum of economic and societal benefits is valued. 

Sibilia Quilici, Executive Director of Vaccines Europe, said: “The pipeline review highlights the innovative approaches and collaborative efforts that are shaping the future of vaccination in Europe. It underscores the importance of remaining competitive through cutting-edge research and streamlined and harmonised regulatory and access processes across the EU and its Member States. By championing life-course immunisation and fostering an environment of innovation, we can ensure that Europe remains at the forefront of global health and economic prosperity.” 

ENDS.